Caliber Imaging & Diagnostics Action

Caliber Imaging & Diagnostics Conversion FCF

Taux de Conversion FCL (FCL/EBITDA) de Caliber Imaging & Diagnostics (LCDX) au 12 août 2026 est 88,79 %.

Conversion FCF

88,79 %

Dernière mise à jour:

Taux de Conversion FCL (FCL/EBITDA) de Caliber Imaging & Diagnostics est 2026 88,79 % . Taux de Conversion FCL (FCL/EBITDA) de Caliber Imaging & Diagnostics était 2025 - . Elle diminue ainsi de % plus faible par rapport à l'année précédente.
Access this data via the Eulerpool API

Caliber Imaging & Diagnostics Analyse d'actions

Que fait Caliber Imaging & Diagnostics ? Caliber Imaging & Diagnostics Inc (CID), founded in 2007, is a medical technology company based in Rochester, New York. CID focuses on the development of optical imaging systems used in the diagnosis of tissue and skin diseases. History CID was founded by an experienced leadership team that previously worked at Kodak, focusing on the development of new imaging technologies. The founders of CID recognized a significant unmet need in the diagnosis of skin diseases, as traditional methods such as biopsies are painful and invasive. Therefore, CID developed a revolutionary technology called VivaScope® that provides a non-invasive, pain-free method of tissue imaging. This technology allows doctors to make quick decisions about a patient without having to wait for a biopsy. Business Model CID aims to distribute its products in the North American market and expand its presence in other regions such as Europe, Asia, and the Middle East. The company strives to benefit from the growing trends in telemedicine and the widespread use of telemedicine tools and wearables. CID has established a trusted relationship with many renowned clinics and medical institutes worldwide to test and validate its VivaScope® technology and increase its presence in the industry. Divisions CID focuses on providing technologies for the diagnosis of skin diseases and tissues. The VivaScope technology is capable of imaging tissue structures beneath the skin surface at a magnification of up to 1000 times. CID offers three main products: VivaScope® System, VivaScope® 1500, and VivaScope® 3000. The VivaScope® System is an advanced diagnostic system approved by the FDA. It uses advanced optics and VegascanTM software to provide TissueMap™ images that allow doctors to visualize tissue beneath the skin surface. The VivaScope® 1500 is a portable version of the VivaScope® system used for the diagnosis of superficial skin diseases such as melanoma, basal cell carcinomas, and actinic keratoses. The VivaScope® 3000 is CID's latest product, offering higher resolution and better image quality than the VivaScope® System or the VivaScope® 1500. Products The VivaScope® system was developed to enable fast, pain-free, and non-invasive diagnosis of skin diseases. The technology of the VivaScope® system allows doctors to visualize tissue structures and cellular changes beneath the skin surface, which can help reduce the number of painful skin biopsies. VivaScope® 1500 is a handheld version of the VivaScope® system that is easy to transport and provides doctors with a mobile diagnostic capability. This device is ideal for the examination of superficial skin diseases such as melanoma, basal cell carcinomas, and actinic keratoses. The VivaScope® 3000 is CID's latest product. This advanced diagnostic system offers higher resolution and better image quality than the VivaScope® system and the VivaScope® 1500. The VivaScope® 3000 features the latest technology and can be used for the analysis of skin and tissue. Conclusion CID is an innovative company specializing in the development of optical imaging systems. The company has developed a revolutionary technology called VivaScope, which helps reduce painful skin biopsies and enables doctors to make quick decisions. With a strong presence in the North American market and a growing interest in telemedicine, CID has all the prerequisites to be a key player in a rapidly evolving industry. Caliber Imaging & Diagnostics est l'une des entreprises les plus populaires sur Eulerpool.

Questions fréquemment posées sur l'action Caliber Imaging & Diagnostics

Taux de Conversion FCL (FCL/EBITDA) de Caliber Imaging & Diagnostics s'élève à 88,79 % en 2026.

Sur Eulerpool, vous trouverez l'évolution historique complète de Caliber Imaging & Diagnostics de Taux de Conversion FCL (FCL/EBITDA) depuis 2006 – avec des valeurs annuelles, des graphiques et une analyse détaillée.

La conversion FCL mesure l'efficacité avec laquelle l'EBITDA se convertit en flux de trésorerie libre. Une conversion plus élevée indique une allocation de capital efficace et des coûts de maintenance faibles.

Un 'bon' varie selon le secteur et le stade de l'entreprise. Sur Eulerpool, vous pouvez comparer Caliber Imaging & Diagnostics de Taux de Conversion FCL (FCL/EBITDA) avec les pairs du secteur et la moyenne du secteur pour évaluer son attrait.

Pour évaluer de Taux de Conversion FCL (FCL/EBITDA), il est essentiel de le comparer avec les pairs du même secteur. Sur Eulerpool, vous pouvez trouver des comparaisons directes du secteur pour Taux de Conversion FCL (FCL/EBITDA).

Access this data via the Eulerpool API

Flux de trésorerie — Caliber Imaging & Diagnostics

Toutes les Métriques Clés — Caliber Imaging & Diagnostics

Croissance